about
Time-to-Onset Analysis of Drug-Induced Long QT Syndrome Based on a Spontaneous Reporting System for Adverse Drug Events[Evaluation of the association between the use of oral anti-hyperglycemic agents and hypoglycemia in Japan by data mining of the Japanese Adverse Drug Event Report (JADER) database].[Adverse Event Trends Associated with Over-the-counter Drugs: Data Mining of the Japanese Adverse Drug Event Report Database].Association between Selective Serotonin Reuptake Inhibitor Therapy and Suicidality: Analysis of U.S. Food and Drug Administration Adverse Event Reporting System Data.A simple and rapid determination of valproic acid in human plasma using a non-porous silica column and liquid chromatography with tandem mass spectrometric detection.Simultaneous determination of benzodiazepines and their metabolites in human serum by liquid chromatography-tandem mass spectrometry using a high-resolution octadecyl silica column compatible with aqueous compounds.Evaluation of Dabigatran- and Warfarin-Associated Hemorrhagic Events Using the FDA-Adverse Event Reporting System Database Stratified by AgeAnalysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug eventsTargeting ceramide synthase 6-dependent metastasis-prone phenotype in lung cancer cells.Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese Adverse Drug Event Report database.Involvement of Mincle and Syk in the changes to innate immunity after ischemic strokeEffects of 14 frequently used drugs on prostate-specific antigen expression in prostate cancer LNCaP cells.Drug-induced gingival hyperplasia: a retrospective study using spontaneous reporting system databasesResveratrol-induced transcriptional up-regulation of ASMase (SMPD1) of human leukemia and cancer cells.Increased acid ceramidase expression depends on upregulation of androgen-dependent deubiquitinases, USP2, in a human prostate cancer cell line, LNCaP.Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-α (TNF-α) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015.Sphingosine kinase 1 plays a role in the upregulation of CD44 expression through extracellular signal-regulated kinase signaling in human colon cancer cells.Sphingosine kinase 1 expression is downregulated during differentiation of Friend cells due to decreased c-MYB.Transcriptional regulation of neutral sphingomyelinase 2 in all-trans retinoic acid-treated human breast cancer cell line, MCF-7.The pivotal role of intracellular calcium in oxaliplatin-induced inhibition of neurite outgrowth but not cell death in differentiated PC12 cells.Sphingosine kinase isoforms regulate oxaliplatin sensitivity of human colon cancer cells through ceramide accumulation and Akt activation.Development of computer-assisted biohazard safety cabinet for preparation and verification of injectable anticancer agents.Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports.Efficacy and safety of micafungin for treating febrile neutropenia in hematological malignancies.Analysis of Neuropsychiatric Adverse Events in Patients Treated with Oseltamivir in Spontaneous Adverse Event Reports.Adenylyl cyclase-cAMP system inhibits thrombin-induced HSP27 in vascular smooth muscle cells.[Evaluation of the Association of Hand-Foot Syndrome with Anticancer Drugs Using the US Food and Drug Administration Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER) Databases].Thromboembolic adverse event study of combined estrogen-progestin preparations using Japanese Adverse Drug Event Report database.Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system.Pediatric thioridazine poisoning as a result of a pharmacy compounding error.Theophylline-associated status epilepticus in an infant: pharmacokinetics and the risk of suppository use.High-performance liquid chromatographic assay of zonisamide in human plasma using a non-porous silica column.High-performance liquid chromatographic assay of clonazepam in human plasma using a non-porous silica column.Stevens-Johnson syndrome and toxic epidermal necrolysis: the Food and Drug Administration adverse event reporting system, 2004-2013.Significant differences in drug lag in clinical development among various strategies used for regulatory submissions in Japan.A highly sensitive assay for ritodrine in human serum by hydrophilic interaction chromatography-tandem mass spectrometry.Analysis of polypharmacy effects in older patients using Japanese Adverse Drug Event Report database.Hypergravity exposure for 14 days increases the effects of propofol in rats.Involvement of tyrosine phosphorylation in inhibition of fMLP-induced PLD activation by N-acetyl-L-cysteine in differentiated HL60 cells.Accidental etizolam ingestion in a child.
P50
Q28554594-993F4113-1110-43C9-B67B-BB58DA1561D2Q30747626-2B7F23E8-DDB9-4936-9B91-C389C19FCAADQ30984489-3D05CB52-A69F-41FB-A2E0-DE820E239DAFQ31014726-61A3237C-E11D-4A77-AA1B-3CF7A15A46E2Q33305643-E5FAB3B4-0797-401B-B254-FB6E07E6B170Q33378143-C49C9DC5-F44C-465E-AEF0-759E5B3D24CCQ35475000-56ABD8E4-13D6-4BB5-9426-3AD608B3043FQ35906730-0325F5CF-B717-4292-8870-E088ACC243FBQ36430767-D56D1958-407F-42FD-9305-CCD3B710879BQ37024628-F36697C0-CBEC-46CF-ADE7-FF8E387D7389Q37293554-A873DA14-B6BE-4C4D-9C37-2504D8565046Q37720026-927AB134-7C13-496C-8786-E72361F4EDB4Q38668962-7617A10F-37D2-461F-8CD6-D90EA8528D01Q38799556-34E33BD6-9CA0-47B8-9962-E9159083EF6AQ38885436-B5B9E6D7-C1BD-432A-B889-76ACFF1D7B8BQ38928600-CF19D856-ECD3-474E-AB67-882439B70B3FQ39191475-8CF422A4-E1B6-42CD-8CCA-0C1BD7AA84E8Q39208983-4C747206-1C32-4E2E-A541-98DFB2F6596DQ39365535-BEA1CEA0-618E-434E-9B6A-CCFA5F22E513Q39461650-EF0D8FEB-F33A-48BC-8E40-713ACFD74AA4Q39880179-7EE2A30F-FD1E-4893-B73B-4FAA2004A903Q39886207-C5AEC0CA-A95C-43C0-A782-4D4AFB2F1273Q40050322-E342257A-D4A8-4CC7-B3F8-A0A59DD2F2DBQ40347435-0EC0A242-E358-4AB2-B810-67FB910C42EEQ40480719-204BAEFA-AA49-41C0-A2DB-2A94B43CC942Q40492082-BE162999-9DDC-46CD-A782-535095ED35F9Q40876118-F8196032-1D1F-4FA1-A329-A7D173EDA929Q41090535-D9BFB3F7-C333-4D30-BE77-E785E41F0E41Q41945537-84A20BB9-79C7-43E6-9927-862B530B0957Q42126335-9104C46F-06F8-4670-89B3-CA822C598C1AQ43242991-63A12FE9-0A24-49CF-951C-2E5E76A2A5A1Q43630877-8463703E-5D8F-4FC4-A70E-EC3CA60C4172Q44929392-2A85A5B5-D658-4312-8416-F064E99297EFQ45910201-6AABEAAB-DDDB-4EC3-8175-D26EE06A1834Q46418687-490CDAB2-3C30-4AA8-9C92-6409B917800EQ46869771-49B887E2-A13C-4862-9FA9-3ADDCF06B278Q47267683-793BA722-B968-4A52-989D-5F1AC0038AB9Q47948697-5E6E0EAF-8726-4C19-8400-25FC846C050EQ47992259-1A0CFB39-72DF-43BE-B9AE-05B496B03B9BQ48578685-CC34DADF-B176-4B5F-BBD3-4200C3DB37CC
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Mitsuhiro Nakamura
@ast
Mitsuhiro Nakamura
@en
Mitsuhiro Nakamura
@es
Mitsuhiro Nakamura
@nl
Mitsuhiro Nakamura
@sl
type
label
Mitsuhiro Nakamura
@ast
Mitsuhiro Nakamura
@en
Mitsuhiro Nakamura
@es
Mitsuhiro Nakamura
@nl
Mitsuhiro Nakamura
@sl
prefLabel
Mitsuhiro Nakamura
@ast
Mitsuhiro Nakamura
@en
Mitsuhiro Nakamura
@es
Mitsuhiro Nakamura
@nl
Mitsuhiro Nakamura
@sl
P106
P21
P31
P496
0000-0002-5062-5522
P569
2000-01-01T00:00:00Z